What are the biggest concerns manufacturers have about the Sunshine Act? FEATURED CONSULTINGMedical Communications What are the biggest concerns manufacturers have about the Sunshine Act?
Will the Sunshine Act eliminate bias from the US healthcare system? FEATURED BLOGSMedical Communications Will the Sunshine Act eliminate bias from the US healthcare system?
Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC Approval BlogMedical CommunicationsOncology Updates Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC
Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma Approval BlogMedical CommunicationsOncology Updates Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma
Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Approval BlogMedical CommunicationsOncology Updates Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Blinatumomab for Patients with MRD-positive B-cell Precursor ALL Approval BlogMedical CommunicationsOncology Updates Blinatumomab for Patients with MRD-positive B-cell Precursor ALL
Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML Approval BlogMedical CommunicationsOncology Updates Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML
Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy Medical CommunicationsOncology Updates Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer Medical CommunicationsOncology Updates Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer
Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer Approval BlogMedical CommunicationsOncology Updates Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer
